Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Core Scientific (CORZ) over the last 5 years, with Q3 2025 value amounting to -$2.9 million.

  • Core Scientific's Gains from Investment Securities fell 47622.79% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year increase of 6358.15%. This contributed to the annual value of $6.0 million for FY2024, which is 6506.29% up from last year.
  • Latest data reveals that Core Scientific reported Gains from Investment Securities of -$2.9 million as of Q3 2025, which was down 47622.79% from -$4.2 million recorded in Q2 2025.
  • Core Scientific's 5-year Gains from Investment Securities high stood at $93.8 million for Q4 2021, and its period low was -$22.2 million during Q2 2022.
  • In the last 5 years, Core Scientific's Gains from Investment Securities had a median value of -$95500.0 in 2021 and averaged $6.6 million.
  • In the last 5 years, Core Scientific's Gains from Investment Securities crashed by 13042352.94% in 2022 and then skyrocketed by 25402.3% in 2024.
  • Over the past 5 years, Core Scientific's Gains from Investment Securities (Quarter) stood at $93.8 million in 2021, then crashed by 32.51% to $63.3 million in 2022, then crashed by 99.61% to $247000.0 in 2023, then skyrocketed by 187.45% to $710000.0 in 2024, then tumbled by 513.1% to -$2.9 million in 2025.
  • Its last three reported values are -$2.9 million in Q3 2025, -$4.2 million for Q2 2025, and $5.0 million during Q1 2025.